Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

23Andme Holding Co. (ME)

23Andme Holding Co. (ME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,265
  • Shares Outstanding, K 26,827
  • Annual Sales, $ 219,640 K
  • Annual Income, $ -666,700 K
  • EBIT $ -228 M
  • EBITDA $ 153 M
  • 60-Month Beta 1.19
  • Price/Sales 0.09
  • Price/Cash Flow 0.20
  • Price/Book 0.26
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -8.54
  • Most Recent Earnings $-1.02 on 01/28/25
  • Next Earnings Date 05/22/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5300 +14.40%
on 03/26/25
2.0700 -70.71%
on 03/17/25
-1.5937 (-72.44%)
since 02/28/25
3-Month
0.5300 +14.40%
on 03/26/25
4.1800 -85.50%
on 01/08/25
-2.6937 (-81.63%)
since 12/27/24
52-Week
0.5300 +14.40%
on 03/26/25
12.7600 -95.25%
on 05/15/24
-10.0337 (-94.30%)
since 03/28/24

Most Recent Stories

More News
Genetic Testing Giant 23andMe Files for Bankruptcy, Putting Personal Data at Risk

American biotechnology company 23andMe filed for Chapter 11 bankruptcy this month, after several quarters of falling revenue. The filing has put the data of millions of users’ data up for grabs, as bidders...

ME : 0.6063 (-21.26%)
How to Tune Out Market Noise

In this podcast, Motley Fool analyst Asit Sharma and host Mary Long discuss:

DKNG : 38.16 (+1.27%)
META : 659.10 (+0.47%)
GOOGL : 165.09 (+3.49%)
NVDA : 135.09 (+3.97%)
GOOG : 166.42 (+3.44%)
AAPL : 211.41 (-0.71%)
FLUT : 247.54 (+2.36%)
F : 10.68 (+0.75%)
MSFT : 451.83 (+0.60%)
MGM : 34.79 (-0.32%)
TSLA : 348.13 (+4.21%)
ME : 0.6063 (-21.26%)
23andMe Stock Is Surging After a Bankruptcy Judge Cleared Genetics Business Sale. Here’s Why You Need to Stay Far Away From ME Shares.

ME stock is surging after its bankruptcy filing, but should you buy the hype?

ME : 0.6063 (-21.26%)
Lifeline For 23andMe? Stock Jumps After Court Greenlights Bankruptcy Asset Sale, Retail Weighs Possible Rescue Deals

Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort....

VHT : 237.75 (-1.72%)
ME : 0.6063 (-21.26%)
VTI : 289.38 (+0.06%)
BIB : 39.80 (-4.05%)
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

ME : 0.6063 (-21.26%)
23andMe Stock Crashes After Bankruptcy Filing—What Happens to Users’ Genetic Data Now?

Shares of 23andMe (NASDAQ: ME) imploded this week after the embattled genetic testing company filed for Chapter 11 bankruptcy and announced the immediate resignation of co-founder and CEO Anne Wojcicki....

GOOG : 166.42 (+3.44%)
GOOGL : 165.09 (+3.49%)
ME : 0.6063 (-21.26%)
23andMe files for Chapter 11 bankruptcy as co-founder and CEO Wojcicki resigns

23andMe has filed for Chapter 11 bankruptcy protection and its co-founder and CEO has resigned as the struggling genetic testing company continues its push to cut costs

$SPX : 5,892.58 (+0.10%)
ME : 0.6063 (-21.26%)
$DOWI : 42,076.71 (-0.15%)
$IUXX : 21,289.82 (+0.43%)
23andMe Just Filed for Bankruptcy and Shares of the DNA Kit Company Are Plunging. Is There Any Hope of a ME Stock Bounce?

23andMe stock crashed as the DNA kit company filed for Chapter 11 bankruptcy on Monday. Investors are recommended to stay away from all the drama.

GM : 50.27 (-0.38%)
ME : 0.6063 (-21.26%)
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

ME : 0.6063 (-21.26%)
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

ME : 0.6063 (-21.26%)

Business Summary

23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition...

See More

Key Turning Points

3rd Resistance Point 1.4375
2nd Resistance Point 1.2688
1st Resistance Point 0.9375
Last Price 0.6063
1st Support Level 0.4375
2nd Support Level 0.2688
3rd Support Level N/A

See More

52-Week High 12.7600
Fibonacci 61.8% 8.0881
Fibonacci 50% 6.6450
Fibonacci 38.2% 5.2019
Last Price 0.6063
52-Week Low 0.5300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar